source
- Acadia’s Alzheimer’s psychosis drug misses primary goal but advances on secondary dataAcadia Pharmaceuticals reported that its investigational drug remlifanserin failed to meet the primary endpoint in the Phase 2 portion of the RADIANT trial for Alzheimer’s disease psychosis. The t…
- Eli Lilly inks $3.35 B China partnership as Immunovant halts lupus drug trialEli Lilly announced a new alliance with Beijing‑based InnoCare Pharma that could be worth up to $3.35 billion. The deal includes an upfront payment of $100 million and up to five target programs fo…